The title of this post is inaccurate and deceiving.
The purpose of the study was "to evaluate the effect of DMF on achieving
no evidence of disease activity (NEDA) "
And actually, the conclusion of the study was:
"A significantly higher percentage of patients treated with DMF achieved NEDA status
over 2 years compared with placebo."
Here is a link to the study:https://www.ncbi.nlm.nih.gov/pubmed/28328179
Per MSUK's own release:
Data analysis of two previous trials has shown that a higher number of patients
with relapsing remitting multiple sclerosis (RRMS) achieved no evidence of disease activity
(NEDA), over a two year period, with delayed-release dimethyl fumarate (DMF) compared to a placebo
In any case, the results seem somewhat favorable anyway. Copaxone was also used in the study and had very similar results.